source
- GSK licenses Chimagen trispecific T-cell engager for up to $750 million, targeting phase-1 multiple myeloma studyGSK has entered a licensing agreement with China’s Chimagen Biosciences that could be worth as much as $750 million. The deal will allow GSK to begin phase‑1 testing of a trispecific T‑cell engager…
- Fourth measles death reported in Pennsylvania, all victims unvaccinatedPennsylvania health officials reported a fourth measles-associated death in the state, involving an 18-year-old from Mifflin County. The death was caused by acute disseminated encephalomyelitis, a…